Biopharma Dismayed US Supreme Court Declines To Take Up Case On Patent Eligibility
Executive Summary
The Court denies a petition for review of American Axle and Manufacturing v. Neapco despite requests from the US government, BIO and former PTO director Kappos that it take up the case to provide greater clarity on the types of inventions that may be patented.
You may also be interested in...
USPTO-FDA Collaboration: Stakeholders Advocate Action From PTAB Proceedings To Examiner Resources
AUTM advocates reform or elimination of inter partes review, DOJ warns of antitrust liability from misrepresentation, and AAM recommends modifying system for measuring productivity of patent examiners.
At Solicitor General’s Urging, Supreme Court May Take Up Patent Eligibility Dispute Riling Biopharma
Federal Circuit’s rulings on subject matter patent eligibility have fractured the court, the US government says in advising the high court to review American Axle v. Neapco to provide clarity. BIO, former PTO director Kappos and Sen. Tillis also urge Supreme Court to hear the case.
Patent Eligibility Bill May Carve Out Patenting Of Research
Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.